A5088370998- Acute Myeloid Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- Lung Cancer Research Studies
- Multiple Myeloma Research and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Peptidase Inhibition and Analysis
- Immune Cell Function and Interaction
- Biosimilars and Bioanalytical Methods
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Hemoglobinopathies and Related Disorders
- Cardiac tumors and thrombi
- Neuroendocrine Tumor Research Advances
- Inflammasome and immune disorders
- Marine Biology and Environmental Chemistry
- Safe Handling of Antineoplastic Drugs
- Genetic Syndromes and Imprinting
- Virus-based gene therapy research
- Hematological disorders and diagnostics
Mayo Clinic in Arizona
2019-2025
WinnMed
2015-2025
Mayo Clinic
2020-2025
Radford University
2023
Alexander Technological Educational Institute of Thessaloniki
2014
Royal Alexandra Children's Hospital
2014
Taylor University
2013
Primary cardiac soft tissue sarcomas (CSTS) affect young adults, with dismal outcomes. The aim of this study was to investigate the clinical outcomes patients CSTS receiving immune checkpoint inhibitors (ICIs). A retrospective, multi-institutional cohort conducted among between 2015 and 2022. were treated ICI-based regimens. Kaplan-Meier method used estimate overall survival (OS) progression-free (PFS). Objective response rates determined according Response Evaluation Criteria in Solid...
Data on the safety profiles and clinical outcomes of patients with solid tumors cardiac metastasis treated immune checkpoint inhibitors (ICIs) are limited. This is an international multicenter retrospective study cancer at baseline. Patients who had received ≥1 dose ICI were included. Treatment-related adverse events (trAEs) graded per Common Terminology Criteria for Adverse Event V.5.0. Objective response rates (ORR) evaluated by Response Evaluation in Solid Tumors V.1.1 when available....
Lurbinectedin has emerged as a potential treatment option for relapsed small cell lung cancer (SCLC). While clinical trials have demonstrated its efficacy and safety, real-world data are limited. This study aimed to evaluate the safety of lurbinectedin in setting, focusing on use second-line agent beyond SCLC patients.
Pleural epithelioid mesothelioma (PEM) is divided into low and high grades based on nuclear atypia, mitoses, necrosis in the tumor. Assessing mitoses atypia tend to be labor-intensive with limited reproducibility. Ki-67 proliferation index was shown a prognostic factor PEM, but its performance has not been directly correlated tumor grade or mitotic score. This study evaluated potential of as surrogate grade. We also compared predictability for overall survival (OS). Ninety-six PEM samples...
TPS2699 Background: Despite the success in hematologic cancers, chimeric antigen receptor (CAR) T-cell therapies are challenging to implement solid tumors owing a lack of tumor-specific targets that discriminate cancer from normal cells. MSLN expression normally is limited mesothelium major body cavities but can be upregulated diverse tumor types (TCGA 2022), making it potential target for therapy. MSLN-targeted cell approaches, including CAR and fusion therapies, have shown promising...
Abstract Background Immune checkpoint inhibitor (ICI) therapy has led to significant improvement in outcomes for patients with nononcogene‐driven advanced non–small cell lung cancer (NSCLC). The rate of crossover and receipt postprotocol ICI frontline trials NSCLC not been systematically evaluated. Methods ClinicalTrials.gov was used identify phase 3 studies evaluating the use immunotherapy or combination chemoimmunotherapy against chemotherapy alone management NSCLC. Data on outcomes,...
TPS2698 Background: Chimeric antigen receptor (CAR) T-cell therapies for treating solid tumors are challenging due to a lack of tumor-specific targets that discriminate cancer from normal cells. Previous studies using CEA receptors and engagers have resulted in dose-limiting, on-target, off-tumor toxicities (1,2). A2B530 is an autologous logic-gated, CEA-targeted Tmod CAR therapy addresses the challenges toxicity by combining CAR-activating with blocking tumor cells (3). The activator...
Chronic neutrophilic leukemia (CNL) is a rare and aggressive BCR-ABL1 (Philadelphia chromosome) negative myeloproliferative neoplasm that carries poor prognosis.It defined by persistent mature leukocytosis, bone marrow granulocytic hyperplasia, hepatosplenomegaly 1 .Despite the 2013 seminal discovery of oncogenic driver mutations in colony-stimulating factor 3 receptor (CSF3R) CNL 2 , no standard care exists.Chemotherapy not able to provide durable responses, literature on allogeneic stem...
<h3>Background</h3> Chimeric antigen receptor (CAR) T-cell therapy has demonstrated clinical efficacy in hematologic malignancies<sup>1</sup>; however, implementation of these therapies solid tumors been challenging due to a lack tumor-specific targets that discriminate cancer from normal cells. Previous studies using carcinoembryonic (CEA) receptors and engagers have resulted dose-limiting, on-target, off-tumor toxicities.<sup>2 3</sup> EVEREST-1 (NCT05736731) is seamless, phase 1/2,...
Seventy percentage of patients who receive paclitaxel have diffuse, refractory myalgias, and arthralgias. Based on anecdotal reports, this study explored whether loratadine, an antihistamine, palliates these symptoms.The medical records postoperative ovarian with endometrial cancer were studied, as are routinely prescribed paclitaxel. Records screened for received loratadine concurrently.Forty the focus report. Eight had paclitaxel-induced myalgias arthralgias then took loratadine; these, 6...
Study Design: This was a retrospective cohort study. Objective: The objective of this study to quantify the rates complication following surgical treatment for symptomatic degenerative and isthmic spondylolisthesis examine association between slip reduction rates. Summary Background Data: It is unclear if degree during lumbar spine fusion in adults influences rate complications. Methods: 1-level 2-level adult patients with or spondylolisthesis. complications were calculated, those without...
<h3>Background</h3> Chimeric antigen receptor (CAR) T-cell therapy has been challenging in solid tumors due to an absence of tumor-specific targets and the resultant on-target, off-tumor toxicity. Tmod, a novel logic-gated CAR therapy, utilizes blocking discriminate tumor from normal cells, thus mitigating toxicity (figure 1).<sup>1 2</sup> The blocker recognizes human leukocyte (HLA), that is subject LOH.<sup>3 4</sup> Among advanced colorectal, pancreatic, non-small cell lung cancers, HLA...
1604 Background: Diversity in clinical studies is essential to address health disparities, but racial and ethnic minorities are often underrepresented studies, especially precision medicine using genetic data (1). BASECAMP-1 (NCT04981119) an ongoing prescreening study identify patients with unresectable advanced or metastatic solid tumors tumor-associated HLA-A*02 LOH for the EVEREST-1 -2 Tmod chimeric antigen receptor T-cell therapy trials. When enrollment began 2021, eligibility Part 1 was...